Diapin Therapeutics
PrivateLast Round
Seed
Jun 21, 2026
Est. Valuation
$9.5M
Total Funding Raised
$3.17M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Diapin Therapeutics operates in Healthcare & Life Sciences and is based in Ann Arbor, Michigan. Its latest recorded funding round was a Grant round in August 2017.
Diapin Therapeutics is a biotechnology company developing novel peptide-based therapies for the treatment of cardiovascular and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diapin Therapeutics Comparables
Compare Diapin Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Structure Therapeutics | 68% | |
| MetaVia Inc. | 68% | |
| Inipharm | 64% |
For institutional investors. Book with your work email.
Diapin Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 21, 2026 | ||||
| Grant | Aug 1, 2017 | ||||
| Grant | Dec 1, 2015 | ||||
| Grant | Feb 1, 2015 | ||||
| Corporate Funding | Dec 17, 2011 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Diapin Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| National Heart, Lung, and Blood Institute | Grant |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Raised $8 million in a seed funding round.
- Apr 17, 2026
Monthly visitors increased 33% MoM, reaching 2.6K.
For institutional investors. Book with your work email.
Diapin Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Diapin Therapeutics's valuation, stock price, and market status.
Is Diapin Therapeutics a public or private company?
Diapin Therapeutics is a private company.
What is the current stock price of Diapin Therapeutics?
Diapin Therapeutics is a private company, so its shares have no public market price. Caplight tracks Diapin Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Diapin Therapeutics worth (valuation)?
Diapin Therapeutics's valuation is estimated at $9.5M based on funding round data.
Can I buy Diapin Therapeutics stock?
Diapin Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Diapin Therapeutics's last funding round?
Diapin Therapeutics's most recent funding round was Seed on June 21, 2026.
Who are the main investors in Diapin Therapeutics?
Key investors in Diapin Therapeutics include National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH).
Will Diapin Therapeutics IPO soon?
No public IPO plans have been announced for Diapin Therapeutics.
How can I track Diapin Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Diapin Therapeutics's shares on secondary markets.